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We have examined the effect that microinjection of 
a monoclonal antibody directed against human DNA 
polymerase-a (SJK-287) has on  DNA synthesis in ex- 
ponentially growing human, mouse, and hamster cell 
lines. We show that the SJK-287 antibody, when mi- 
croinjected directly into the nuclei of cells  is capable 
of inhibiting DNA synthesis in all three cell lines 
tested. Moreover, the effectiveness with which this 
antibody can inhibit ongoing DNA synthesis by the 
microinjection assay is closely correlated with the abil- 
ity of the antibody to neutralize DNA polymerase-a 
activity fractionated from each  cell  line in vitro. Two 
other monoclonal antibodies of the same class, one 
directed against the cellular p53 protein (PAb122), 
and one directed against the c-myc protein (PM-8) 
were also tested for their ability to inhibit ongoing 
DNA synthesis by direct microinjection and in lysole- 
cithin permeabilized cells. Both monoclonal antibodies 
failed to inhibit ongoing DNA synthesis in exponen- 
tially  growing  cells by these assays. 
Numerous  studies have demonstrated  that microinjection 
of antibody molecules into  mammalian cells in  culture  can be 
used to investigate the role that the antigen, to which the 
antibodies  are  directed,  has  in  the processes of cell prolifera- 
tion.  This  approach is based  on  the  initial findings that: 1) 
antibodies  can be microinjected into cells without  apparent 
toxicity  (1-9); 2) microinjected IgG anti  SV40-T  antigen 
inhibits SV40-induced cell DNA synthesis (4, 6), and viral 
replication (3); 3) however, IgG anti  SV40-T  antigen does not 
inhibit  serum-stimulated  DNA  synthesis  (4,6);  4)  control IgG 
microinjected into  the nuclei of quiescent cells  does not  inhibit 
serum-stimulated DNA or RNA synthesis, or accumulation 
(4-8). A monoclonal antibody directed against the cellular 
p53  protein  designated PAb122, when microinjected into 
quiescent cells at  or very near  the  time of serum-stimulation 
can inhibit entry into S-phase (5-7). However, this same 
antibody  when microinjected into  S-phase cells  does not  in- 
hibit ongoing DNA  synthesis (5). This  latter  result  prompted 
us to ask whether or not ongoing DNA synthesis could be 
inhibited by antibody microinjection, when the monoclonal 
antibody is directed  against  DNA  polylmerase-a. 
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DNA  polymerase-a is the  principal  eukaryotic polymerase 
implicated in semi-conservative DNA replication  (for review, 
see Refs. 10  and 11). It is a general  observation that growing 
cells contain a high level of DNA polymerase-a that may 
represent  as  much  as 90% of the  total cellular DNA polym- 
erase  activity  (10). Biochemical inhibitors  that  can  differen- 
tiate between  purified polymerase-a, -p, and -y activities i n  
vitro implicate  polymerase-a  in semi-conservative replication 
of DNA  in permeabilized  cell systems (12-14) and  in isolated 
nuclei (15). 
A panel of murine hybridoma cell lines which produce 
monoclonal antibodies  against  human  DNA  polymerase-a  has 
been developed (16, 17). In vitro neutralization  assays have 
demonstrated  that  these  antibodies  are specific and show no 
cross-reactivity  (as assessed by sensitive  binding  assays)  with 
DNA polymerase-@ or -y (16).  Moreover,  some of these  anti- 
bodies are capable of inhibiting  DNA  polymerase-a  directed 
nuclear DNA synthesis in a lysolecithin-permeabilized cell 
system (18, 19). 
We have examined  the effect that microinjection of one of 
these monoclonal antibodies  designated  SJK-287  has  on  DNA 
synthesis in intact exponentially growing cells from three 
different mammalian species. In addition, we have directly 
compared  the effect of the  SJK-287  antibody  and two other 
monoclonal antibodies PAb122, directed  against  the  p53  pro- 
tein,  and  PM-8  directed  against  the c-myc protein  on  DNA 
synthesis by direct microinjection and by incubating these 
same  antibodies  with lysolecithin-permeabilized cells. 
EXPERIMENTAL PROCEDURES’ 
RESULTS 
Effect of Microinjected Antibodies on D N A  Synthesis- 
Recently studies of Miller et al. (18, 19) have demonstrated 
that  antibodies  directed  against  human  DNA  polymerase-a 
substantially inhibit nuclear synthesis in cells which have 
been irreversibly  permeabilized by lysolecithin treatment.  The 
degree to which DNA  synthesis  is  inhibited  in  this  system  is 
proportional  to  the  antibody  concentration used. We  exam- 
ined the effect that one of these anti-DNA polymerase-a 
monoclonal antibodies,  SJK-287,  and two other monoclonal 
Portions of this paper (including “Experimental Procedures,” 
Tables I1 and 111, and Figs. 2-4) are presented in miniprint at  the 
end of this paper. The abbreviations used are: BHK, baby hamster 
kidney; PBS, phosphate-buffered saline. Miniprint is easily read with 
the aid of a standard magnifying glass. Full size photocopies are 
available from the  Journal of Biological Chemistry, 9650 Rockville 
Pike, Bethesda, MD 20814. Request Document No. 86M-0056, cite 
the authors, and include a check or  money order for $3.60 per set of 
photocopies. Full size photocopies are also included in the microfilm 
edition of the  Journal  that is available from Waverly Press. 
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TABLE I 
Effect of microinjected antibodies  on DNA synthesis in exponentially 
growing cell lines 
Exponentially growing human, hamster, and mouse cells were 
microinjected with one of the four antibodies listed above: mouse 
monoclonal antibodies,  anti-DNA  polymerase-n  (SJK-287);  anti-p53 
(PAb122); anti-myc (PM-8), or control mouse IgG.  At 1 h after 
microinjection, the  cells were pulse-labeled for 30 min with 10 pCi/ 
ml ['Hlthymidine, fixed, and  then processed for autoradiography as 
described previously (5).  The percentage of labeled cells was deter- 
mined by light microscopy after Giemsa staining. 
~- " .  ~. ~ _ _ _ ~  
Cell line/antibody 
rnicroiniected Fraction of labeled cells 
-~ -~ "" 
microinjected/bockRround 
Human (T98G) 
SJK-28'7 0.36 
PAb122 0.98 
IgGs 0.95 
PM-8  0.92 
Hamster (tsAF8) 
SJK-287 0.51 
PAb122 0.90 
IgCs 0.98 
PM-8 1.05 
Mouse (3T3) 
SJK-287  0.65 
PAb122 0.97 
IgGs 1.02 
PM-8  0.92 
." .. ~ - "" ~ - 
antibodies, PAb122 and  PM-8  (directed  against nuclear cell 
cycle-dependent oncogene products),  have  on DNA synthesis 
in exponentially growing human, hamster, and mouse cell 
lines following direct nuclear microinjection. SJK-287 is a 
mouse monoclonal antibody directed against human DNA 
polymerase-cu developed by Tanaka  et al. (16).  This  antibody 
inhibits DNA synthesis in lysolecithin-permeabilized human 
cells (18, 19) and exhibits in uitro neutralizing activity of 
polymerase-cu activity (16, 18). PAb122 is a  monoclonal anti- 
body directed against the mouse p53 protein developed by 
Gurney et al. (25).  This  antibody recognizes both mouse and 
human p53 nuclear protein (7, 25, 27). PM-8 is a mouse 
monoclonal antibody directed against bacterially produced 
human c-myc (28)  protein  and  is  capable of immunoprecipi- 
tating a  65-kD protein from a human leukemic cell line CCRF- 
CEM (Fig. 4) and from phytohemagglutinin-stimulated hu- 
man peripheral blood lymphocytes, but  not from resting lym- 
phocytes.2 
The  results of these microinjection experiments  are  present 
in  Table I. The  fraction of labeled cells is  presented  as  the 
ratio of microinjected to background cells in these experi- 
ments  to  indicate  the relative level of inhibition observed  for 
each cell line  examined. 
The  data in Table I  shows that  antibody  directed  against 
DNA polymerase-a (SJK-287) when microinjected into the 
nuclei of exponentially growing T98G cells is capable of 
inhibiting DNA synthesis by 64%.  In  contrast,  control  non- 
immune IgG, anti-p53  (PAb122),  or  anti-c-myc (PM-8), when 
microinjected at  roughly the  same  concentrations as the  anti 
DNA polymerase-a  antibodies have  very little if any, effect 
on DNA synthesis in this cell line. Fig. 1, a and b, show 
autoradiographs of T98G cells  microinjected  with PAb122(a) 
or SJK-287(b) antibodies. From the observed decrease in 
nuclear  ["Hlthymidine labeling  in Fig. Ib,  it  is  apparent  that 
the microinjected anti-DNA  polymerase-a  antibody  is  capable 
of inhibiting nuclear DNA synthesis  in uiuo. This  confirms 
and  extends  the  observation of Miller et al. (18) who showed 
* L. Kaczmarek, M. R. Miller, R. A. Hammond, and W. E. Mercer, 
unpublished results. 
FIG. 1. Photomicrograph of exponentially  growing human 
T98C cells  microinjected with monoclonal antibodies: a, cell 
microinjected with  anti-p53 (PAb122); b, cells microinjected 
with anti-DNA polymerase-a (SJK-287). Cells were microin- 
jected with monoclonal antibodies as described. At 1 h after microin- 
jection,  the  cells were pulse-labeled with 10 pCi/ml of ["Hlthymidine 
for 30  min, fixed and processed for autoradiography. Magnification 
is X400. 
that  the  same  antibody can inhibit nuclear DNA replication 
in uitro, in lysolecithin-permeabilized human cells. That  the 
inhibition we observe following microinjection of SJK-287 is 
not  simply due  to aspecific  toxicity  resulting from the  intro- 
duction of antibodies  to nuclear protein antigens, is suggested 
by the observation that PAb122 and PM-8 antibodies (di- 
rected against nuclear  protein antigens) fail to inhibit DNA 
synthesis  (Table I and Fig. la);  and, from our previous find- 
ings that an antibody directed against RNA polymerase I 
(another nuclear protein), does not inhibit DNA synthesis, 
but is capable of inhibiting nucleolar RNA synthesis and 
accumulation when  microinjected into cells (9). 
Time Course of Inhibition by Anti DNA Polymerase-a  An- 
tibody-While cells selectively permeabilized by lysolecithin 
exhibit acceptable preservation of gross structural integrity 
and  the  capacity  to  carry  out  synthesis of DNA,  RNA, and 
protein at  near in uiuo rates for a short period of time (29- 
31); such cells are  nonetheless irreversibly damaged and  thus 
the long range effect of antibodies  in  this system cannot be 
ascertained. In  order  to  determine  the long  range effect that 
the  SJK-287  antibody  has  on DNA replication in intact living 
cells, we microinjected this  antibody  into  human T98G cells 
and  examined  its affect on  the capacity of cells to synthesize 
DNA as a function of time  after injection. 
In  these  experiments T98G cells were microinjected with 
SJK-287  antibody  and at  different  times  after injection the 
cells were pulse-labeled with ["Hlthymidine,  then processed 
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for autoradiography. The results of these experiments are 
presented in Table I1 (Miniprint).  The  ability of the  SJK-287 
antibody  to  inhibit  DNA  synthesis decreases with  time  after 
the  initial microinjection. For example, T98G cells microin- 
jected with SJK-287  at  time 0 and pulse-labeled  for 30 min at  
5 h after injection exhibit a 37%  inhibition of DNA  synthesis 
relative to  the  62%  inhibition observed  when  cells are  microin- 
jected with the  antibody,  and  then pulse-labeled at  1 h after 
injection  (Table 11). 
In  contrast,  with cells microinjected at  time 0 with  SJK- 
287 antibody  and pulse-labeled a t  20 h after  injection, only 
an  18% inhibition of DNA  synthesis  is observed. These  ex- 
periments were repeated several times  and gave essentially 
the  same  results, suggesting that  the  inhibition of DNA  syn- 
thesis observed in cells microinjected with SJK-287 is not 
simply due  to aspecific  toxicity of the  antibody  preparation. 
Effect of Ant i   DNA Polymerase-a  Antibodies on DNA Po- 
lymerase from Different Mammalian Species-Previous re- 
sults have demonstrated  the  neutralizing  activity of SJK-287 
antibody  on DNA polymerase-a  fractions  prepared from hu- 
man diploid fibroblasts  and from malignant  human  KB cell 
line  against which the  antibody was initially  directed (16, 18). 
Because little  has been reported  about  the  interspecies reac- 
tivity of this  antibody, we thought  it would be worthwhile to 
test  its  neutralizing effect on  DNA  polymerase-a  activity  in 
comparative  experiments  with  crude  DNA  polymerase-a  frac- 
tions prepared from each line. The  results of these experi- 
ments  are  shown in Fig. 2 (Miniprint).  The  data  presented  in 
Fig. 2  shows that  the  SJK-287  antibody  is  able  to  neutralize 
crude DNA polymerase-a fractions prepared from human, 
hamster,  and mouse  cells in a concentration-dependent  man- 
ner.  The  neutralizing  titer of the  SJK-287  antibody for the 
DNA polymerase activities from different species is given in 
the legend of Fig. 2 (Miniprint).  From  the  data  presented,  it 
is  clear  that  the effective antibody  titer required to  neutralize 
50% of the  DNA  polymerase-a  activity  in mouse and  hamster 
cells is considerably  higher than  that required to  neutralize 
an  equivalent  activity of DNA  polymerase-a  in  human cells. 
Species  Specificity of Microinjected Anti-DNA Polymerase- 
a Antibody-In order to determine whether the decreased 
ability of antibody  SJK-287  to  neutralize mouse and  hamster 
DNA  polymerase-a  activities in vitro (relative  to  human po- 
lymerase-a) also  occurs in vivo, an  equivalent  concentration 
of SJK-287 antibody was microinjected into the nuclei of 
exponentially growing human,  hamster,  and mouse cells. 
Anti-p53  antibody  (PAb122)  and  anti-myc  antibody  (PM-8) 
were also microinjected, in  this  study.  The  results  are  sum- 
marized in  Table I. The  SJK-287  antibody  appears  to more 
efficiently  inibit  DNA  synthesis  in  human cells than  in  ham- 
ster or mouse cell lines. These  experiments were repeated at 
least twice with similar results. The i n  vitro neutralization 
results presented in Fig. 2 (Miniprint) agree well with the 
observed efficiency of in vivo inhibition of DNA synthesis 
following  microinjection of the  SJK-287  antibody  into each 
cell line. The data also indicates that antibodies directed 
against p53 or c-myc proteins have little, if any, effect on 
DNA  synthesis  in  S-phase cells. 
Effect of DNA Polymerase-a  Antibodies on  DNA  Synthesis 
in Permeable Cells-We also  wanted  to directly compare  the 
effects of microinjected antibody  SJK-287  on  DNA  synthesis 
in viable  cells with  its effects on  DNA  synthesis  in permeable 
cells. 
T98G cells were therefore permeabilized with lysolecithin 
and  the ffects of SJK-287  on  DNA  synthesis was determined. 
Fig. 3 (Miniprint) shows that  SJK-287  inhibited  DNA  syn- 
thesis in  permeable T98G cells in a dose-dependent  manner. 
However, when corrected for  cell number, significantly  higher 
levels of SJK-287 were required to  inhibit  DNA  synthesis in 
permeable T98G cells than reported (18, 19) for permeable 
HF cells (Fig. 3).  The  ability of antibody  SJK-287  to  inhibit 
DNA  polymerase-a  activity  extracted from T98G  or HF  cells 
was therefore directly determined.  When expressed as picom- 
oles of SJK-287/105 cells, approximately 9-fold higher con- 
centrations of antibody SJK-287 were required to inhibit 
DNA polymerase-a actvity from T98G cells than from HF 
cells. This  is due to  the  fact  that 9-10-fold higher levels of 
polymerase-a were present  in lo5 T98G cells than  in lo5 HF 
cells. Essentially  identical  titration curves of antibody  SJK- 
287 were obtained  for  equal  activities of polymerase-a from 
T98G  and  HF cells (not shown). The higher levels of polym- 
erase-a  in  T98G cells appear  to  account for the higher con- 
centrations of antibody SJK-287 required to inhibit DNA 
synthesis  in permeable T98G cells than in  permeable HF cells 
(Fig.  3). As previously reported  (19), much  higher concentra- 
tions of antibody  SJK-287 were required to  inhibit nuclear 
DNA synthesis in permeable cells than were required to 
reduce polymerase-a  activity  extracted from the  same  number 
of permeable cells. In  contrast  to  studies with  permeable HF  
cells which are  quite  consistent,  the  amount of inhibition of 
DNA synthesis in permeable T98G cells by antibody SJK- 
287 was more  variable. This  variability is reflected in several 
points in Fig. 3 (Miniprint) which are not on the titration 
curve. In several experiments, very little  inhibition of DNA 
synthesis by even high concentrations of SJK-287 was ob- 
served. The reason for this variability in permeable T98G 
cells is  not  yet known.  Antibodies directed  against  proteins 
p53  or c-myc had  little, if any, effect on  DNA  synthesis  in 
permeable T98G  or HF cells. 
DISCUSSION 
In this  paper, we have examined  the  ability of a  monoclonal 
antibody  (SJK-287)  directed  against  human  DNA polymer- 
ase-a  (16)  to  inhibit ongoing DNA synthesis when directly 
microinjected into  the nuclei of exponentially growing cells 
from three different mammalian species. In addition, two 
other monoclonal antibodies of the  same class, and  directed 
against  the cell-cycle dependent p53 (27, 32, 33) and c-myc 
(34-36) oncogene products were also examined for their ability 
to  inhibit ongoing DNA  synthesis by the microinjection, and 
by the lysolecithin  permeabilized  cell assays (18, 19). 
The novel findings in this  paper are: 1) by direct nuclear 
microinjection into  intact living cells, the  SJK-287  antibody 
can efficiently inhibit ongoing DNA  synthesis  in  human,  and 
albeit  to a  lesser  degree, in mouse and  hamster cells as well; 
2) by comparative in vitro neutralization assays a higher 
antibody  concentration is required to  neutralize  an  equivalent 
amounts of polymerase-a activity fractionated from mouse 
and  hamster cell lines  than from human cells; 3)  in  exponen- 
tially growing human cells, when assayed by direct nuclear 
microinjection or when incubated  with  lysolecithin-permea- 
bilized cells, neither PAb122 nor  PM-8 monoclonal antibodies 
are  able  to  inhibit ongoing DNA  synthesis. 
The  SJK-287  antibody  has previously been shown to  neu- 
tralize DNA polymerase-a activity in vitro (16, 18) and is 
capable of inhibiting  DNA  synthesis in certain lysolecithin- 
permeabilized human cells (18,19). By immunocytochemistry 
most, if not all, of the polymerase-a molecules have been 
localized to  the nucleus of growing cells, but  are  not  detectable 
by this  method  in  nonproliferating cells (17). Although our 
microinjection results for human T98G cells with SJK-287 
are not intrinsically surprising, especially in view  of the 
previous results with other permeabilized human cells (18, 
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19); neither,  are  they  entirely  predictable a priori. 
The microinjection assay utilizes intact living cells; and 
therefore, it was not predictable a priori that  the  SJK-287 
antibody would have  the  same effect on DNA synthesis in. 
uiuo as  have previously been  demonstrated  in  the  permeabil- 
ized cell system (18, 19). That is, it is not predictable that 
active  nuclear  polymerase-a molecules (17) engaged in  semi- 
conservative  chromosomal  DNA  synthesis in uiuo would be 
fully assessable  to  the  inhibitory  action f this  antibody.  This 
is especially true  in view of current  concepts of a putative 
organized multienzyme replication complex composed of a 
number of interacting  protein  components (37-39). However, 
our  results clearly  show that  the  SJK-287  antibody  can effi- 
ciently inhibit ongoing DNA synthesis when microinjected 
into  intact living  cells (Table I). 
Our  finding  that  the  SJK-287  antibody  can  also  neutralize 
polymerase-a  activity in uitro and  inhibit ongoing DNA  syn- 
thesis in uiuo in mouse and  hamster cells lines  is of interest. 
This  is  to  our knowledge, the  first  report of interspecies  cross- 
reactivity of this particular monoclonal antibody; however, 
Wang et al. (40)  have  recently  reported  on  the species-specific 
interaction of other  anti-polymerase-a  antibodies.  It  is  note- 
worthy  that  the  results of our  comparative in uitro neutrali- 
zation  assays show that a higher concentration of SJK-287 is 
required to  neutralize an  equivalent  amount of polymerase-a 
activity  fractionated  from mouse and  hamster cell lines  than 
from  human cell  lines. 
By the  direct microinjection assay,  the  SJK-287  antibody 
is also less  efficient a t  inhibiting ongoing DNA  synthesis  in 
mouse and  hamster cell lines than  in  human cells.  Differences 
in  the  reactivity of this  same  antibody  have  also been  observed 
with  polymerase-a  fractions  purified  from  untransformed  hu- 
man diploid fibroblasts  and  from  malignant  human  KB cells 
(18), and from human T98G glioblastoma cells (Fig. 3). At 
high concentrations of antibody, which are  sufficient  to  in- 
hibit  polymerase-a  actvity  fractionated from KB cells by 95%, 
almost 20 and 40%  of the  polymerase-a  activity  from HF  and  
T98G cells,  respectively, remains  detectable. The reason for 
the observed  difference in  reactivity of this  antibody  to  polym- 
erase-a  activity  within  and between mammalian species is at 
present  unclear. 
Neither PAb122 or  PM-8  monoclonal  antibodies  inhibited 
ongoing DNA  synthesis  in  exponentially growing human cells, 
either by direct nuclear microinjection or when incubated 
with lysolecithin permeabilized cells (Table I and Fig. 3). 
Previous microinjection studies using PAb122 have shown 
that this antibody can block serum-stimulated progression 
into  S-phase (5, 6); however, the  same  antibody  is  incapable 
of inhibiting ongoing DNA  synthesis  in  synchronized  S-phase 
cells ( 5 ) ,  or in exponentially growing cells (our present re- 
sults).  The  failure of PAb122 and  (PM-8)  to  inhibit ongoing 
DNA synthesis in cells may imply that these nuclear cell 
cycle-dependent oncogene products  are  not as intimately as- 
sociated  with  the processes of semi-conservative  DNA  syn- 
thesis as DNA  polymerase-a; especially, since  an  equivalent 
concentration of each antibody was microinjected directly 
into  the nucleus of cells or  incubated  with permeabilized cells. 
An alternative  explanation  is  that  in  S-phase cells antigenic 
determinants  on  p53  or  c-myc  proteins may simply not be 
accessible to antibody binding for inhibition to occur. I t  is 
also  noteworthy t o  mention  thatsall  attempts  to  inhibit  the 
entry of resting cells into  S-phase following serum  stimulation 
by microinjection of the PM-8 antibody  (or  other  antibodies 
directed against human c-myc proteins) under conditions 
where anti-p53  antibodies  inhibit  or a t  least delay entry  into 
S-phase  have failed.3 
Monoclonal antibodies, because of their high  specificity of 
action  can  be  used  as specific inhibitors of target molecules; 
and  thus,  can  be gainfully  employed to  study  the role of these 
target molecules in the processes of cell proliferation. In 
addition to  being able  to  introduce  antibody molecules directly 
into  the nucleus of living  cells, the microinjection assay allows 
one  to  study  some processes such  as  the  resting to growing 
transition of cells,  which  does not occur in irreversibly per- 
meabilized cell systems. In  contrast,  some biochemical studies 
which can be performed in the permeabilized cell system 
cannot be performed  on microinjected cells. 
For  instance,  incorporation of radioactive precursors  into 
macromolecules can  be readily quantitated by liquid scintil- 
lation  counting in  permeabilized cells, but  autoradiography  or 
microphotometry  must  be employed in microinjection studies 
(5-8). Moreover, in permeabilized  cells by “pulse/chase” ex- 
periments we have  recently shown that  the  SJK-287  antibody 
inhibits both the synthesis and the maturation of Okazaki 
DNA (19); such  studies  cannot be performed  in  microinjected 
cells. Finally, our work suggests that  the  direct nuclear  mi- 
croinjection  assay  coupled with  the permeabilized cell assay 
may be useful to  distinguish between nuclear  protein  antigens 
critically important  to  the  immediate process of ongoing semi- 
conservative  DNA  synthesis from those more closely associ- 
ated  with cell-cycle progression into  S-phase (41, 42). 
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Cell lines and culture d t i o n s :  
calf sennn at 34'C 120, 211. Ts AF8 cells are a G1"ific  t-ature sensitive cell 
Syrian h t e r  tsAp8 cells were mintaid in hrlbecm's d i m  mntaining 100 &nor 
cycle outant  of !+$?x cells  originally  isolated by -stin et al. 1221. The ts  pr-ty of 
this mhant xas m t  used in  this  stwly.  swiss 3 3  muse cella were maintained  at 37-c in 
hrlbecm's d i m  mntaining 100  fetal  calf se- as described  previously  151.  T98G 
h m  glloblastara cell6 1231 were maintained  in Earle's minim1 essential d i m  
containing  vitamins and 100 fetal  calf se- at 37'c. Hs24F IHF) h m  diploid 
fitnoblasts 118) were mintaid in 450 Dulbecco's d i m ,  450 H a n ' s  F-10 d i m  with 100 
fetal  calf 8em at 3 7 F .  "an cells, derived f m  peripheral bled of a patient 
with  acute  lynphoblastic lakemi= were mintaid in WMI 1640 d i m  mntaining 100 
fetal  calf em at 37-C as previously  described 1271. 
mlonal Antibodies: 
al., I161 and is d i r d  against  hrnan rn polyerases The PAbl22 m m l o ~ l  antibody 
(Is11 &vel& by Gurney et al. (251 is  directed  against mxlse p53  protein,  but ala0 
FU-8 antibody  is a muse m m l d  antibody IIs31  directed  against a 
r-nizes " n t s  on h m  (but  not  hamster)  p53  proteins 17, 25,  271. The 
bacterially-prooduced h- c- protein 1281. FU-8 a b  a kid gift  of Dr. G. Rover= 
and mntro l  nonimmme muse Is's uaed in  this stdy were prepared as previously 
Iwistar Institute  of RnaW and Biolosy.  Philadelphia,  Pa.) All m m 1 0 ~ 1  antibodies, 
desribed ( 7 ) .  
Microinjection pr-e: 
The STK-287 antibody  is a rimuse mmlonal antibody 1 1 s  281 &el- by Tanalca et 
The  glass-ilky  microin3ection prmedures deyeloped by G r a e s m  and G r a e s m  
(241 with  the dification for  antibody  microinjection  described by us (7.8.91 -6 used 
to introduce m m l o d  antitdies lor c ~ t r o l  antibodies)  directly  into  the  nuclei  of 
exponentially gravlng cells. We first determined the effect  that  the SJK-287 antibody 
has on rn synthesis  in h- T98G cells at different  times  after  initial  microinjection 
of the antibody.  T98G cells -e microiniected  with STK-287 antibody  pr-ation  and at 
different e& after  injection the cells-were pulselabeled  for 30 miiutes with 1 0 ~  
Ci/ml  of 1383 thyvidine ( 6 . 7  Ci/mle; New England Nuclear Cop. Bxltcn, ml, =shed 
three times  in m' kdamx salt mlution, fixed  in ~ethaMl, and subsequently 
processed  for  autoradiography acmrding to itmdard prmedures.  The  perc&tage-of 
labeled cella xas determined by light  microsccpy  after  Gi-  staining. The SJK-287 
magnitude  of  inhibition decreases with  tire  (Table 11, miniprint). These expc-ts 
antibody hen microinjected  into  TPBG cells efficiently  inhibits rn synthesis and the 
were repeated  several  times  with  essentially similar results. In all expecinents, the 
mimm inhibition  of LW. synthesis  18s observed when cells e r e  labeled at 1 hr 
post-injection. 
In all subsqwnt  experhems, cells were microinjected  with the antibodies under 
study and labeled at 1 m. after  injection. By this  procedure one is m u r i n g  the 
effect  that  microinjected  antibodies have on w i n g  rn synthesis  in S- cells, 
rather than the  effect on cell cycle prqression frm a resting to gravlng stage 17) .  
T a b l e  I11 (mini  print1 shous the  results  of  dilution experhts using the SJK-287 
antibody, The initial  m-tration  of  the STK-278 antibody IBE 5 ng of  protein/ml  of 
described by the mufacturers. The results shar that a 1:lO dilution lO.hg/mll of 
solotion as determined by protein  assay  (Bio-Rad  protein  assay  kit, 1500-00011 as 
STK-278 is  still capable of  inhibiting ONIL synthesis by 290; m e r ,  at a 1:lOO dilution 
ralution  that can be delivered to intact  viable cells using the glass-illary new is 
10.05 rqs/mll the  inhibition obeerved after  microinjection  is  only 120. Ths a m m t  of 
abut 1 x 10-1l ml/nucleus 1241. At a protein  m-tration  of hghd, m e  can calmlate 
armylt  is  sufficient to inhibit OWL synthesis ~cnpletely in mst injected  cells 1- 
that appraxhtely 0 . 0 5 ~  of I s  CM be delivered to each nucleus. In T98G cells, this 
figure 1, text). 
-recipitation and W Electrcphoresis; 
tested  for  their  ability to inrmnoprecipitate  e53 and myc proteins frm h- cells. m he 
p r d u r e  for  inmumprecipitation and polyacrylamide gel dectrcphoresis  in 100 slab gels 
has been described in detal1 1271 The h m  cell line c c w a  XBP used to prepare 
C3'81 "ethionine  11063.6 ci/ ml;, ~ e v  England Nuclear corp. -ton, ml labeled protein 
eXtract8  for  inrmnoprecipitation. The results  of  these xpchts are shasl in pig. 4. 
miniprint. By imMncpercnidase  staining as dffribed previously 1271 bth PAb 122 and 
PM-8 m m l 0 ~ 1  antibodies raognize antigenic determimats in h- ~ 9 %  cells hich are 
lwlized prinarily  within  the nw1- ( m t  n h ) .  
In Vitro m l m a s e  "Assaw and Antibody  t&utralizations: 
lhkxlonal antibodies  PAb122 and p H 8  used in  the  microinjection  expecinenta were 
The STK-287 antibody  preparations used for  microinjection were ala0 tested  for  their 
ability to neutralize m p o l m - - o  stivity in protein fractims prepared 
~0lyerase-o fractians were p e r f a d  a8 previously  described  in  detail (16,181. I" 
fron hman, hanster and -e cell lines. These assays and the  preparation  of OWL 
different  mncentrations  of  antibody  for 60 minutes at OT, and then p1-m activity 
these V h t s ,  identical ammts of rn plyerase-o Mivity -e incubated  with 
Y I S  determined as desribed (XI. The results are shaa in  Fig. 2 miniprint. 
Cell Pemmablization and OWL %thesis msays:  
PIotcM1s for  permaabilizing  cells  with  lysolecithin and m u r i n g  rn replication 
have been described  in  detail 118,19). Results are -ressed as 0 inhibition  of OWL 
of  antibody  m-tration  per 105 cells. This  facilitated  -ison of the effect  of 
synthesis by anti OWL plyerase-mantibody, relative to control antibody, as a fmtion 
The results are shasl in  Fig. 3 miniprint. 
antibodies on OWL replication  in permsable  cells and OWL pol-ase-cactivity i n .  
In this 8tu3y S a m  differences were abserved in the efficiency  with  rhich  the 
STK-287 antibody  inhibited OWL synthesis by microinjection -ed to that abserved hen 
antibody  efficiently  inhibited rn synthesis by 62-700 in  -tially growing T98G 
the  antibody res incubated  with w i l i z e d  cells. Microinjectian  of the SJK-287 
cells (Table 1. text and Table I1 and 111. miniprint); vhereas I" the 
permaabilired cell system, the STK-287 antibody minally redu%d OWL aynulesis  in cells 
by only 10-450 (Fig 3 miniprint).  he differ-  in the efficiency  with  which  the 
"287 antibody  inhibited  ongoing OWL synthesis by the  direct  nicroinjgticn  assay 
relative to the  permsabilized  cell  assay can m t  be attriblted to a limited mncentration 
of  anti-  in the latter  assay. At high  antibody  carentraticns (50 vg of SJK-287 in a 
50 ul voltme), if  nuclei are freely -le to the antibody, 106 permaable cell nuclei 
wuld  mtain - 0 . 5  ug of STK-287, aich is mre antibody than can be microinjected  into 
Therefore, microinjection w s  to be mre efficient than the penneabilized cell  
the nvlei of cells;and thus,  should prwide a greater reduction of OWL eymthsis. 
system. htst  likely,  this  ia  due to the fact  that  antibody mlecules are directly 
introduced  into  the  nuclei of cells by the microinjection technique; and thus, the 
cells (19). 
mlear e a n e  dDes mt pose a barrier to the  antibodies. as it dDes in prmabilired 
lnBm I1 
Tine mure Of  inhibition  of D m  synthesis  in  exFmentially gravlng T98G  cells by 
microinjected STK-287 antibody 
Tine Of  labelling  Fraction  of [ % I  thpidine 
after  microinjection labeled cells 0 Inhibition 
( h r l  cmicroinjected/kkqrordI 
1 
3 
5 
20 
0.38 
0.57 
0.63 
0.82 
62 
i 3  
18 
37 
microinjected  at 2 day  after plating. The SJK-287 antibody res microinjected at tine 
T98G cells were plated at 5x104 cella/6h petri  dish in  culture d i m  and 
z a o  and the  cells were pulse-labeled  far 30 minutes at  the  times  indicated mve and 
subsequently  fixed and pro~eesed for  autoradiography. The nlnnber of  labeled cells in 
mcroinjected and tackgram3 (no" microinjected) cells gr-ng on the same -slip m?, 
determined by light  micro-y (see Fig. 1. text) 
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E f f e t  of an t ikdy   d i lu t ion  on the ab i l i t y   o f  SJK-287 to inh ib i t  OWL synthesis  in T98G 
cells 
Antitcdy  dilution Ract ion  of [%I  thpidine 
lateled cells 
(Fnicminjetedihckgraud) 
S Inhibit ion 
UlX3iluted 
1: 1 
1: 10 
1: 100 
1: 1000 
0.30 
0.60 
0.71 
0.95 
0.88 
m 
40 
29 
12 
05 
&kccclonal a n t i m y  YK-287 was p r e p ~ e d  at a p r o t e i n   m m t r a t i o n  of %Ad as 
&scribed by W e e r  et al. (7). U d l u t e d  preparations. or pr-ations di luted in  PES 
were microinjeaed into exponentially graring T98G cells. The cells -e labeled with 
[ % I  thymidine 85 d e r r i b e d   i n  (Table I, text) - 
ug MAB I ml 
Pig. 2. Neutralizaticn  of polyner-o ac t iv i ty  by mnrrlonal antitcdy (ml 
YK-287. Neutralization t i t r a t i m  -e p e r f o d  as described (16,181 using 
m e  unit  of OWL p l - a s e o  prepared f r m   d i f f e r e n t  cells l ines.  (A I ,  
h m  T98G: C 0 I harmter, tsAF8; I 0 I ,  mx?e 3 3 .  The a n t i k d y  titer 
( u g h 1  suf f ic ien t  to neutralize one unit   of m4 pol-ase-o ac t iv i ty  by 50% is 
0.03 for h m  T98G. 0.5 for harmter tsRP8. and 3.5 for  m5e 3T3 cells. 
respectively. 
BO I 
70 t / 
Lop p o l e  IqGAO’ Cells 
Pig. 3 Tk e f f e t  of antikcdy SJK-287 m OWL p o l y n e r e a a c t i v i t y  and m 
repl icat ion in  HF cells and ~98G cells. m plynerase-o (frerr ion 1) ces 
prepared f r m  HF and T98G cells as d e r r i b e d ,  and the a b i l i t y  of d i f fe ren t  
mmentrat ions  of  SJK-287 to inh ib i t  m pl” act iv i ty  ces determined. 
Results are  expressed as % inhibit ion of ONA plyrerase- o. ac t iv i ty  extracted 
a function of ant ikdy  mncentrat ion;  i.e., 10s (-le STK-287/105 cells.) w 
frm lo5 cells ( re la t ive  to m n t r o l s  assayed i n  the absence of antL.todies) as 
plynerasea I I i T99: plynerase-o ( o ). For ONA synthesis studies,  4 1 s  
were p n m a b i l i z e d   w i t h   l y s o l e i t h i n  and pre iMbated   wi th   d i f fe ren t  
mrrentrati-  of a n t i k d y  SJK-287. Tbe incorporation of I 31  TCP in to  m was 
determined as described (18). Results are expressed as % inhibit ion of m 
synthesis   in  105 -le cells as a function of ant ikdy  comentrat ion:  
rep~cted studies 118) and d e t e r m i d   i n  this study I, I:  T98G ONA synthesis 
i.e., log I-le YK-287/105 cells). HF OWL synthesis ( A I frm pr-iwsly 
I A I .  OWL synthesis  in  permeable HF and T98; cells vas inhibited 5% by high 
mnlent ra t iON of a n t i  p53 and a n t i  qc a n t i t d i e s  (data mt s M ) .  
and E= no& mn&e I-. lblgular e i g h t  narkeri’are indicated by 
br i zon ta l ‘  l i nes  and are, f r m  top totton. b i n e  sem albmrin I69.0001 and 
ovalhnnin (46.000). 
